GERN GERON CORP
Pharmaceutical Preparations · Nasdaq · SEC CIK 886744 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY40.2%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-20.1%
ROA-8.7%
ROIC (approx.)-8.9%
Asset turnover—
Leverage & solvency
Liabilities / assets57.0%
Debt / equity0.53x
Current ratio6.31x
Interest coverage-1.11x
Cash quality & payout
Operating cash flow / net income1.89x
Accruals ratio7.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $60.19M | $57.48M | $51.84M | — | $47.23M | $49.04M | $39.60M | — |
| R&D expense | $12.71M | $22.03M | $14.96M | $13.55M | $21.07M | $21.74M | $15.08M | $23.43M |
| SG&A expense | $35.70M | $38.86M | $35.42M | $41.67M | $39.00M | $38.56M | $40.02M | $43.37M |
| Operating income | $5.80M | -$12.50M | $158,000 | -$25.54M | -$13.89M | -$12.45M | -$16.70M | -$20.05M |
| Interest expense | $7.21M | $7.15M | $7.15M | $7.30M | $8.64M | $8.52M | $8.20M | $8.71M |
| Net income | $1.35M | -$16.68M | -$3.64M | -$28.86M | -$18.43M | -$16.38M | -$19.84M | -$25.35M |
| EBITDA | $5.94M | -$12.36M | $292,000 | -$25.45M | -$13.76M | -$12.33M | -$16.57M | -$19.91M |
| EPS (basic) | 0.00 | -0.02 | -0.01 | — | -0.03 | -0.02 | -0.03 | — |
| EPS (diluted) | 0.00 | -0.02 | -0.01 | — | -0.03 | -0.02 | -0.03 | — |
| Weighted avg. shares (diluted) | 674.05M | 670,696 | 669,375 | — | 667.10M | 666,170 | 665,905 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $69.18M | $62.64M | $68.89M | $77.56M | $78.12M | $77.73M | $83.75M | $79.02M |
| Short-term investments | — | — | — | — | — | — | — | $327.55M |
| Receivables | $45.98M | $51.64M | $41.88M | $36.99M | $35.36M | $36.61M | $31.17M | $35.95M |
| Inventory | $126.60M | $123.60M | $133.29M | $116.64M | $95.42M | $69.12M | $56.22M | $38.71M |
| Current assets | $468.74M | $486.34M | $498.53M | $520.27M | $522.34M | $505.60M | $495.77M | $490.99M |
| PP&E, net | $1.11M | $1.09M | $1.00M | $884,000 | $973,000 | $1.19M | $1.15M | $1.31M |
| Total assets | $527.11M | $519.01M | $534.12M | $570.54M | $567.38M | $555.20M | $562.45M | $593.78M |
| Current liabilities | $74.25M | $70.33M | $73.57M | $111.54M | $87.71M | $64.28M | $63.03M | $88.30M |
| Short-term debt | — | — | — | — | — | — | $0 | $0 |
| Long-term debt | $120.44M | $120.13M | $119.83M | $119.55M | $119.26M | $118.99M | $118.73M | $118.48M |
| Total debt | $120.44M | $120.13M | $119.83M | $119.55M | $119.26M | $118.99M | $118.73M | $118.48M |
| Total liabilities | $300.41M | $300.39M | $305.01M | $344.67M | $318.68M | $295.67M | $294.21M | $313.46M |
| Shareholders' equity | $226.69M | $218.61M | $229.11M | $225.87M | $248.71M | $259.53M | $268.24M | $280.32M |
| Net debt | $51.26M | $57.49M | $50.94M | $41.99M | $41.15M | $41.26M | $34.98M | $39.46M |
| Shares outstanding | — | — | — | 639.86M | — | — | — | 606.39M |
| Cash flow statement | ||||||||
| Operating cash flow | $10.27M | -$15.83M | -$62.91M | -$22.07M | -$13.58M | -$27.41M | -$47.98M | -$43.95M |
| Capital expenditure | — | — | — | — | — | — | — | -$141,000 |
| Free cash flow | — | — | — | — | — | — | — | -$43.80M |
| Investing cash flow | -$5.91M | $8.29M | $51.86M | $21.14M | $13.35M | $20.32M | $52.44M | -$103.51M |
| Financing cash flow | $2.17M | $1.38M | $2.42M | $378,000 | $542,000 | $1.09M | $256,000 | $166.16M |
| Depreciation & amortization | $137,000 | $136,000 | $134,000 | $87,000 | $128,000 | $128,000 | $131,000 | $142,000 |
| Stock-based compensation | $4.81M | $4.95M | $4.91M | $5.70M | $6.74M | $6.74M | $7.42M | $6.79M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.